ClinicalTrials.Veeva

Menu

Abdominal aBscess Catheter Sclerotherapy (ABCS)

The University of Alabama at Birmingham logo

The University of Alabama at Birmingham

Status and phase

Begins enrollment in 6 months
Phase 2
Phase 1

Conditions

Abdominal Abscess

Treatments

Drug: Catheter Sclerotherapy

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06906029
000548435 (Other Grant/Funding Number)
IRB-300014540

Details and patient eligibility

About

This is a single center, two arm phase I/II clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. The target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. The primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.

Full description

This is a two-arm prospective phase I/II clinical trial to assess the safety of a protocol of catheter-based drainage and povidone iodine or ethanol sclerotherapy of non-fistulous intraabdominal abscesses. The study aims to enroll approximately 60 total subjects with 30 per arm. The abscess should be intraperitoneal with a minimum diameter of 3cm in all three dimensions and devoid of suspicion for relation to a fistula. The described technique above will be employed to place a drainage catheter of minimum 14F in caliber and obtain an antimicrobial sample. Saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. Following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. After approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. The catheter will then be removed, and the site dressed with gauze and film dressing. The patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female, aged over 18years
  • Cross-sectional imaging (CT, US, MRI) showing an intraabdominal abscess measuring at last 3cm in each dimension without fistula to the bowel or skin.
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

  • Pregnancy or lactation
  • Known allergic reactions to povidone iodine or ethanol
  • Hemodynamic instability

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Iodine Arm
Active Comparator group
Description:
Catheter-based drainage and povidone iodine sclerotherapy of non-fistulous intraabdominal abscesses.
Treatment:
Drug: Catheter Sclerotherapy
Ethanol Arm
Active Comparator group
Description:
Catheter-based drainage and ethanol sclerotherapy of non-fistulous intraabdominal abscesses.
Treatment:
Drug: Catheter Sclerotherapy

Trial contacts and locations

1

Loading...

Central trial contact

Evan Husdon, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems